[Form 4] Kura Oncology, Inc. Insider Trading Activity
Kura Oncology SVP, Finance & Accounting Thomas Doyle acquired 24,966 shares of Kura common stock on 09/27/2025 at a reported price of $0, increasing his direct holdings to 114,370 shares. On 09/29/2025 he sold 4,541 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes tied to the vesting of 1/6th of performance-based restricted stock units (PSUs). The filing notes that one performance milestone was achieved on 09/27/2025, triggering the vesting event for that tranche; the Reporting Person also reports 500 shares indirectly held in a spouse's 401(k). After the transactions the Reporting Person beneficially owns 109,829 shares.
Il Senior Vice President di Kura Oncology, Finanza e Contabilità, Thomas Doyle, ha acquisito 24.966 azioni ordinarie di Kura il 27/09/2025 a un prezzo riportato di $0, aumentando le sue partecipazioni dirette a 114.370 azioni. Il 29/09/2025 ha venduto 4.541 azioni a $8.9422 per azione come operazione di vendita per coprire tasse legate al vesting di 1/6 delle unità azionarie restritte basate sulle performance (PSU). La dichiarazione segnala che un traguardo di performance è stato raggiunto il 27/09/2025, attivando l’evento di vesting per quella tranche; la persona riportante riporta anche 500 azioni detenute indirettamente nel 401(k) del coniuge. Dopo le transazioni, la persona riportante detiene beneficiariamente 109.829 azioni.
El SVP de Kura Oncology, Finanzas y Contabilidad, Thomas Doyle, adquirió 24.966 acciones comunes de Kura el 27/09/2025 a un precio reportado de $0, aumentando sus participaciones directas a 114.370 acciones. El 29/09/2025 vendió 4.541 acciones a $8.9422 por acción como una operación de venta para cubrir impuestos vinculados al vesting de 1/6 de las unidades de acciones restringidas basadas en rendimiento (PSU). El archivo señala que se alcanzó un hito de rendimiento el 27/09/2025, lo que activó el vesting para esa porción; la persona informante también reporta 500 acciones poseídas indirectamente en el 401(k) del cónyuge. Después de las transacciones, la persona informante posee de forma beneficiosa 109.829 acciones.
Kura Oncology의 재무 및 회계 수석 부사장 Thomas Doyle은 2025년 9월 27일 Kura 보통주 24,966주를 보고된 가격 $0에 취득하여 직접 보유 주식이 114,370주로 증가했습니다. 2025년 9월 29일에는 4,541주를 주당 $8.9422로 매도하여 성과 기반 제한 주식 단위(PSU)의 vesting과 관련된 세금을 충당하기 위한 매도-커버 거래를 수행했습니다. 제출서는 9/27/2025에 하나의 성과 이정표가 달성되어 해당 구간의 vesting 이벤트가 촉발되었다고 기록합니다; 보고 당사자는 또 배우자의 401(k)에서 간접 보유된 500주를 보고합니다. 거래 후 보고 당사자는 유리하게 109,829주를 보유하게 됩니다.
Le vice-président exécutif des finances et de la comptabilité chez Kura Oncology, Thomas Doyle, a acquis 24 966 actions ordinaires de Kura le 27/09/2025 à un prix affiché de $0, portant ses avoirs directs à 114 370 actions. Le 29/09/2025, il a vendu 4 541 actions à $8.9422 par action dans le cadre d’une opération de vente pour couvrir les impôts liés au vesting de 1/6 des unités d’actions restreintes liées à la performance (PSU). Le dossier indique qu’un jalon de performance a été atteint le 27/09/2025, déclenchant l’événement de vesting pour cette tranche; la personne déclarante reporte également 500 actions détenues indirectement dans le 401(k) de son/sa conjoint(e). Après les transactions, la personne déclarante détient bénéficiairement 109 829 actions.
Kura Oncology Senior Vice President Finanzen & Rechnungswesen Thomas Doyle erwarb am 27.09.2025 24.966 Stammaktien von Kura zu einem gemeldeten Preis von $0, wodurch seine direkten Beteiligungen auf 114.370 Aktien zunahmen. Am 29.09.2025 verkaufte er 4.541 Aktien zu $8.9422 pro Aktie im Rahmen einer Sell-to-Cover-Transaktion, um Steuern im Zusammenhang mit dem Vesting von 1/6 der performance-basierten Restricted Stock Units (PSUs) zu decken. Die Einreichung vermerkt, dass am 27.09.2025 ein Leistungsmeilenstein erreicht wurde und das Vesting-Ereignis für diese Tranche ausgelöst wurde; die berichtende Person meldet außerdem 500 Aktien, die indirekt im 401(k) des Ehepartners gehalten werden. Nach den Transaktionen besitzt die berichtende Person vorteilhaft 109.829 Aktien.
أعلن نائب الرئيس الأول للمالية والمحاسبة في كورا أونكولوجي توماس دويل عن استحواذه على 24,966 سهماً عائداً من أسهم كورا في 27/09/2025 بسعر معلن $0، مما زاد حصته المباشرة إلى 114,370 سهماً. في 29/09/2025 باع 4,541 سهماً بسعر $8.9422 للسهم كصفقة بيع لتغطية الضرائب المرتبطة بحدوث vesting لـ1/6 من وحدات الأسهم المقيدة المرتبطة بالأداء (PSU). تشير الوثائق إلى أنه تم بلوغ معلم أداء في 27/09/2025، مما أدى إلى تفعيل حدث vesting لهذه الشريحة؛ كما يذكر الشخص المبلغ عنه أن لديه 500 سهم مملوكون بشكل غير مباشر في 401(k) الخاص بالزوج/الزوجة. بعد هذه المعاملات يملك الشخص المبلغ عنه بشكل مستفيد 109,829 سهمًا.
Kura Oncology 财务与会计高级副总裁 Thomas Doyle 于 2025-09-27 以披露价格 $0 收购了 24,966 股 Kura 普通股，使其直接持有增加到 114,370 股。于 2025-09-29 他以每股 $8.9422 的价格出售 4,541 股，作为卖出覆盖交易，用以支付与绩效为基础的受限股票单位（PSU）归属相关的税款。文件指出，在 2025-09-27 实现了一个绩效里程碑，触发该批次的归属事件；报告人还报告在配偶的 401(k) 中间接持有 500 股。交易完成后，报告人实际持有 109,829 股。
- 24,966 shares vested on 09/27/2025, reflecting achievement of a PSU performance milestone
- Significant retained ownership after transactions: 109,829 shares beneficially owned
- 4,541 shares sold on 09/29/2025 at $8.9422 per share (sell-to-cover for taxes)
Insights
TL;DR: Insider received PSUs that vested and sold a small tranche to cover taxes, leaving substantial ownership.
The 24,966-share acquisition at a reported price of $0 represents settlement/vesting of equity awards rather than an open-market purchase; the concurrent sell-to-cover of 4,541 shares at $8.9422 is a routine tax-related disposition. Net ownership remained large at 109,829 shares, indicating continued equity alignment with shareholders. This disclosure does not provide company-level financial metrics, valuation context, or signal a change in executive control. The activity is material only to the extent it reveals milestone achievement under PSU grants.
TL;DR: Governance action: performance milestone met triggering vesting; standard sell-to-cover executed for tax withholding.
The filing documents a governance-triggered compensation event: one specified development milestone was met on 09/27/2025, causing vesting of 1/6th of PSUs granted 05/31/2023. Such milestone-based vesting is a common performance alignment mechanism. The signature and timely Form 4 filing comply with Section 16 reporting. No departures, option exercises for cash, or transfers to affiliates are disclosed. The indirect holding of 500 shares in a spouse's 401(k) is properly reported.
Il Senior Vice President di Kura Oncology, Finanza e Contabilità, Thomas Doyle, ha acquisito 24.966 azioni ordinarie di Kura il 27/09/2025 a un prezzo riportato di $0, aumentando le sue partecipazioni dirette a 114.370 azioni. Il 29/09/2025 ha venduto 4.541 azioni a $8.9422 per azione come operazione di vendita per coprire tasse legate al vesting di 1/6 delle unità azionarie restritte basate sulle performance (PSU). La dichiarazione segnala che un traguardo di performance è stato raggiunto il 27/09/2025, attivando l’evento di vesting per quella tranche; la persona riportante riporta anche 500 azioni detenute indirettamente nel 401(k) del coniuge. Dopo le transazioni, la persona riportante detiene beneficiariamente 109.829 azioni.
El SVP de Kura Oncology, Finanzas y Contabilidad, Thomas Doyle, adquirió 24.966 acciones comunes de Kura el 27/09/2025 a un precio reportado de $0, aumentando sus participaciones directas a 114.370 acciones. El 29/09/2025 vendió 4.541 acciones a $8.9422 por acción como una operación de venta para cubrir impuestos vinculados al vesting de 1/6 de las unidades de acciones restringidas basadas en rendimiento (PSU). El archivo señala que se alcanzó un hito de rendimiento el 27/09/2025, lo que activó el vesting para esa porción; la persona informante también reporta 500 acciones poseídas indirectamente en el 401(k) del cónyuge. Después de las transacciones, la persona informante posee de forma beneficiosa 109.829 acciones.
Kura Oncology의 재무 및 회계 수석 부사장 Thomas Doyle은 2025년 9월 27일 Kura 보통주 24,966주를 보고된 가격 $0에 취득하여 직접 보유 주식이 114,370주로 증가했습니다. 2025년 9월 29일에는 4,541주를 주당 $8.9422로 매도하여 성과 기반 제한 주식 단위(PSU)의 vesting과 관련된 세금을 충당하기 위한 매도-커버 거래를 수행했습니다. 제출서는 9/27/2025에 하나의 성과 이정표가 달성되어 해당 구간의 vesting 이벤트가 촉발되었다고 기록합니다; 보고 당사자는 또 배우자의 401(k)에서 간접 보유된 500주를 보고합니다. 거래 후 보고 당사자는 유리하게 109,829주를 보유하게 됩니다.
Le vice-président exécutif des finances et de la comptabilité chez Kura Oncology, Thomas Doyle, a acquis 24 966 actions ordinaires de Kura le 27/09/2025 à un prix affiché de $0, portant ses avoirs directs à 114 370 actions. Le 29/09/2025, il a vendu 4 541 actions à $8.9422 par action dans le cadre d’une opération de vente pour couvrir les impôts liés au vesting de 1/6 des unités d’actions restreintes liées à la performance (PSU). Le dossier indique qu’un jalon de performance a été atteint le 27/09/2025, déclenchant l’événement de vesting pour cette tranche; la personne déclarante reporte également 500 actions détenues indirectement dans le 401(k) de son/sa conjoint(e). Après les transactions, la personne déclarante détient bénéficiairement 109 829 actions.
Kura Oncology Senior Vice President Finanzen & Rechnungswesen Thomas Doyle erwarb am 27.09.2025 24.966 Stammaktien von Kura zu einem gemeldeten Preis von $0, wodurch seine direkten Beteiligungen auf 114.370 Aktien zunahmen. Am 29.09.2025 verkaufte er 4.541 Aktien zu $8.9422 pro Aktie im Rahmen einer Sell-to-Cover-Transaktion, um Steuern im Zusammenhang mit dem Vesting von 1/6 der performance-basierten Restricted Stock Units (PSUs) zu decken. Die Einreichung vermerkt, dass am 27.09.2025 ein Leistungsmeilenstein erreicht wurde und das Vesting-Ereignis für diese Tranche ausgelöst wurde; die berichtende Person meldet außerdem 500 Aktien, die indirekt im 401(k) des Ehepartners gehalten werden. Nach den Transaktionen besitzt die berichtende Person vorteilhaft 109.829 Aktien.
FAQ
What insider transactions did Thomas Doyle report on Form 4 for KURA?
Why were shares sold on 09/29/2025 in the KURA Form 4?
How many KURA shares does the reporting person own after these transactions?
What triggered the vesting of the PSUs reported on the Form 4?
Are there any indirect holdings disclosed by the reporting person?
